Cartesian Therapeutics Grants 6,100 Stock Options to New Hire at $5.86
Updated
Updated · GlobeNewswire · Jun 12
Cartesian Therapeutics Grants 6,100 Stock Options to New Hire at $5.86
3 articles · Updated · GlobeNewswire · Jun 12
Summary
June 8 marked Cartesian Therapeutics' grant of an inducement option covering 6,100 common shares to one new employee, with an exercise price of $5.86.
The award was issued under Nasdaq Rule 5635(c)(4) as a hiring inducement, using the company's amended 2018 employment inducement incentive plan and board approval.
25% of the option vests on June 8, 2027, with the rest vesting in 36 roughly equal monthly installments through June 8, 2030; the option carries a 10-year term.
Cartesian, a late clinical-stage biotech focused on autoimmune disease cell therapies, is advancing lead candidate Descartes-08 in Phase 3 for generalized myasthenia gravis.